AGRX logo

Agile Therapeutics (AGRX) EBITDA

Annual EBITDA

-$12.66 M
+$12.76 M+50.20%

December 31, 2023

Summary

Performance

1-Year Change

+50.2%

3-Year Change

+73.88%

5-Year Change

+33.78%

15-Year Change

+51.98%

AGRX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$12.66 M
AGRX annual EBITDA is currently at an all-time high

3-Year Low

-$64.93 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
AGRX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

N/A
AGRX next annual earnings announcement has not yet been scheduled

OtherAGRXprofitabilitymetrics:

Annual Revenue

$19.59 M
AGRX annual revenue is $19.59 million

Annual Net Income

-$14.46 M
AGRX annual net profit is -$14.46 million

Annual EBIT

-$13.05 M
AGRX annual earnings before interest & taxes is -$13.05 million

Annual EPS

-$6.71
AGRX annual earnings per share is -$6.71

Quarterly EBITDA

-$11.77 M
-$13.34 M-848.73%

June 1, 2024

Summary

Performance

3-Month Change

-848.73%

1-Year Change

-252.18%

3-Year Change

+26.87%

5-Year Change

-241.56%

AGRX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$1.57 M
AGRX quarterly EBITDA is currently -848.73% below its historical high of $1.57 million

3-Year Low

-$17.95 M

Earnings dates

Last Quarterly Earnings Report Date

Jun 1, 2024
AGRX previous earnings announcement was published on Jun 1, 2024

Next Quarterly Earnings Report Date

N/A
AGRX next earnings announcement has not yet been scheduled

OtherAGRXprofitabilitymetrics:

Quarterly Revenue

$5.58 M
AGRX quarterly revenue is $5.58 million

Quarterly Net Income

-$11.87 M
AGRX quarterly net profit is -$11.87 million

Quarterly EBIT

-$11.87 M
AGRX quarterly earnings before interest & taxes is -$11.87 million

Quarterly EPS

-$1.73
AGRX quarterly earnings per share is -$1.73

TTM EBITDA

-$14.62 M
-$8.43 M-136.05%

June 1, 2024

Summary

Performance

3-Month Change

-136.05%

1-Year Change

+10.34%

3-Year Change

+76.75%

5-Year Change

+20.71%

AGRX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$4.22 M

3-Year Low

-$64.93 M

Earnings dates

Last Quarterly Earnings Report Date

Jun 1, 2024
AGRX previous earnings announcement was published on Jun 1, 2024

Next Quarterly Earnings Report Date

N/A
AGRX next earnings announcement has not yet been scheduled

OtherAGRXprofitabilitymetrics:

TTM Revenue

$21.57 M
AGRX TTM revenue is $21.57 million

TTM Net Income

-$15.86 M
AGRX TTM net profit is -$15.86 million

TTM EBIT

-$15.03 M
AGRX TTM earnings before interest & taxes is -$15.03 million

TTM EPS

-$3.13
AGRX TTM earnings per share is -$3.13

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$12.66 M
AGRX annual EBITDA is -$12.66 million

Annual Net Income

-$14.46 M
AGRX annual net profit is -$14.46 million

Annual Interest Expense

$1.42 M
AGRX annual interest expense is $1.42 million

Annual Income Tax

$0.00
AGRX annual income tax is $0.00

Annual D&A

$386.00 K
AGRX annual depreciation & amortization is $386.00 thousand

AGRX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+50.2%-252.2%+10.3%
3 y3 years+73.9%+26.9%+76.8%
5 y5 years+33.8%-241.6%+20.7%

AGRX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+412.9%-848.7%+52.5%+136.0%+344.0%
5 y5-yearat high+412.9%-848.7%+52.5%+136.0%+344.0%
alltimeall timeat high+412.9%-848.7%+52.5%+246.2%+344.0%

Agile Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Jun 2024
-
-$11.77 M(-848.7%)
-$14.62 M(+136.0%)
Mar 2024
-
$1.57 M(-138.7%)
-$6.20 M(-51.1%)
Dec 2023
-$12.66 M(-50.2%)
-$4.07 M(+1029.2%)
-$12.66 M(+5.5%)
Sep 2023
-
-$360.00 K(-89.2%)
-$12.01 M(-26.4%)
Jun 2023
-
-$3.34 M(-31.7%)
-$16.31 M(-2.5%)
Mar 2023
-
-$4.89 M(+43.6%)
-$16.72 M(-34.2%)
Dec 2022
-$25.42 M(-60.8%)
-$3.41 M(-26.9%)
-$25.42 M(-36.4%)
Sep 2022
-
-$4.66 M(+24.3%)
-$39.97 M(-20.9%)
Jun 2022
-
-$3.75 M(-72.4%)
-$50.53 M(-19.6%)
Mar 2022
-
-$13.60 M(-24.3%)
-$62.87 M(-3.2%)
Dec 2021
-$64.93 M(+34.0%)
-$17.95 M(+18.0%)
-$64.93 M(+2.2%)
Sep 2021
-
-$15.22 M(-5.4%)
-$63.51 M(+1.0%)
Jun 2021
-
-$16.09 M(+2.8%)
-$62.90 M(+11.0%)
Mar 2021
-
-$15.66 M(-5.3%)
-$56.69 M(+17.0%)
Dec 2020
-$48.47 M(+162.8%)
-$16.53 M(+13.1%)
-$48.47 M(+27.8%)
Sep 2020
-
-$14.62 M(+48.0%)
-$37.92 M(+36.9%)
Jun 2020
-
-$9.88 M(+32.8%)
-$27.69 M(+30.3%)
Mar 2020
-
-$7.44 M(+24.5%)
-$21.26 M(+15.3%)
Dec 2019
-$18.44 M(-3.5%)
-$5.98 M(+36.1%)
-$18.44 M(+14.5%)
Sep 2019
-
-$4.39 M(+27.5%)
-$16.11 M(+5.7%)
Jun 2019
-
-$3.45 M(-25.5%)
-$15.23 M(-9.4%)
Mar 2019
-
-$4.63 M(+26.9%)
-$16.81 M(-12.1%)
Dec 2018
-$19.12 M
-$3.64 M(+3.6%)
-$19.12 M(-10.2%)
DateAnnualQuarterlyTTM
Sep 2018
-
-$3.52 M(-29.9%)
-$21.30 M(-12.8%)
Jun 2018
-
-$5.02 M(-27.7%)
-$24.42 M(-7.3%)
Mar 2018
-
-$6.94 M(+19.1%)
-$26.33 M(-0.1%)
Dec 2017
-$26.36 M(-10.2%)
-$5.82 M(-12.3%)
-$26.36 M(-6.7%)
Sep 2017
-
-$6.64 M(-4.3%)
-$28.24 M(-1.3%)
Jun 2017
-
-$6.94 M(-0.4%)
-$28.62 M(-3.1%)
Mar 2017
-
-$6.96 M(-9.6%)
-$29.55 M(+0.7%)
Dec 2016
-$29.35 M(-14.2%)
-$7.70 M(+9.8%)
-$29.35 M(-5.2%)
Sep 2016
-
-$7.01 M(-10.8%)
-$30.96 M(-5.6%)
Jun 2016
-
-$7.87 M(+16.2%)
-$32.80 M(-0.2%)
Mar 2016
-
-$6.77 M(-27.4%)
-$32.87 M(-3.9%)
Dec 2015
-$34.21 M(+88.5%)
-$9.31 M(+5.2%)
-$34.21 M(+9.1%)
Sep 2015
-
-$8.86 M(+11.6%)
-$31.35 M(+10.2%)
Jun 2015
-
-$7.93 M(-2.1%)
-$28.45 M(+19.4%)
Mar 2015
-
-$8.11 M(+25.7%)
-$23.83 M(+31.3%)
Dec 2014
-$18.15 M(+41.9%)
-$6.45 M(+8.2%)
-$18.15 M(+32.1%)
Sep 2014
-
-$5.96 M(+79.9%)
-$13.74 M(+23.9%)
Jun 2014
-
-$3.31 M(+36.2%)
-$11.09 M(+0.7%)
Mar 2014
-
-$2.43 M(+19.7%)
-$11.01 M(-14.0%)
Dec 2013
-$12.80 M(-44.6%)
-$2.03 M(-38.6%)
-$12.81 M(+18.9%)
Sep 2013
-
-$3.31 M(+2.2%)
-$10.77 M(+44.3%)
Jun 2013
-
-$3.24 M(-23.3%)
-$7.46 M(+76.7%)
Mar 2013
-
-$4.22 M
-$4.22 M
Dec 2012
-$23.10 M
-
-

FAQ

  • What is Agile Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Agile Therapeutics?
  • What is Agile Therapeutics annual EBITDA year-on-year change?
  • What is Agile Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Agile Therapeutics?
  • What is Agile Therapeutics quarterly EBITDA year-on-year change?
  • What is Agile Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Agile Therapeutics?
  • What is Agile Therapeutics TTM EBITDA year-on-year change?

What is Agile Therapeutics annual EBITDA?

The current annual EBITDA of AGRX is -$12.66 M

What is the all time high annual EBITDA for Agile Therapeutics?

Agile Therapeutics all-time high annual EBITDA is -$12.66 M

What is Agile Therapeutics annual EBITDA year-on-year change?

Over the past year, AGRX annual EBITDA has changed by +$12.76 M (+50.20%)

What is Agile Therapeutics quarterly EBITDA?

The current quarterly EBITDA of AGRX is -$11.77 M

What is the all time high quarterly EBITDA for Agile Therapeutics?

Agile Therapeutics all-time high quarterly EBITDA is $1.57 M

What is Agile Therapeutics quarterly EBITDA year-on-year change?

Over the past year, AGRX quarterly EBITDA has changed by -$8.43 M (-252.18%)

What is Agile Therapeutics TTM EBITDA?

The current TTM EBITDA of AGRX is -$14.62 M

What is the all time high TTM EBITDA for Agile Therapeutics?

Agile Therapeutics all-time high TTM EBITDA is -$4.22 M

What is Agile Therapeutics TTM EBITDA year-on-year change?

Over the past year, AGRX TTM EBITDA has changed by +$1.69 M (+10.34%)